IBDEI0KH ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9695,0)
 ;;=67028^^43^554^6^^^^1
 ;;^UTILITY(U,$J,358.3,9695,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9695,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,9695,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,9696,0)
 ;;=67500^^43^554^10^^^^1
 ;;^UTILITY(U,$J,358.3,9696,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9696,1,2,0)
 ;;=2^Retrobulbar Inj,Medication
 ;;^UTILITY(U,$J,358.3,9696,1,3,0)
 ;;=3^67500
 ;;^UTILITY(U,$J,358.3,9697,0)
 ;;=67505^^43^554^9^^^^1
 ;;^UTILITY(U,$J,358.3,9697,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9697,1,2,0)
 ;;=2^Retrobulbar Inj,Alcohol
 ;;^UTILITY(U,$J,358.3,9697,1,3,0)
 ;;=3^67505
 ;;^UTILITY(U,$J,358.3,9698,0)
 ;;=68200^^43^554^13^^^^1
 ;;^UTILITY(U,$J,358.3,9698,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9698,1,2,0)
 ;;=2^Subconjunctival Injection
 ;;^UTILITY(U,$J,358.3,9698,1,3,0)
 ;;=3^68200
 ;;^UTILITY(U,$J,358.3,9699,0)
 ;;=96372^^43^554^11^^^^1
 ;;^UTILITY(U,$J,358.3,9699,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9699,1,2,0)
 ;;=2^SC/IM Injection
 ;;^UTILITY(U,$J,358.3,9699,1,3,0)
 ;;=3^96372
 ;;^UTILITY(U,$J,358.3,9700,0)
 ;;=96402^^43^554^12^^^^1
 ;;^UTILITY(U,$J,358.3,9700,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9700,1,2,0)
 ;;=2^SQ/IM Anti-Neplastic Hormone Inj
 ;;^UTILITY(U,$J,358.3,9700,1,3,0)
 ;;=3^96402
 ;;^UTILITY(U,$J,358.3,9701,0)
 ;;=C9257^^43^554^2^^^^1
 ;;^UTILITY(U,$J,358.3,9701,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9701,1,2,0)
 ;;=2^Bevacizumab Inj 0.25mg
 ;;^UTILITY(U,$J,358.3,9701,1,3,0)
 ;;=3^C9257
 ;;^UTILITY(U,$J,358.3,9702,0)
 ;;=J1094^^43^554^4^^^^1
 ;;^UTILITY(U,$J,358.3,9702,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9702,1,2,0)
 ;;=2^Dexamethasone Acetate Inj per 1mg
 ;;^UTILITY(U,$J,358.3,9702,1,3,0)
 ;;=3^J1094
 ;;^UTILITY(U,$J,358.3,9703,0)
 ;;=J2778^^43^554^8^^^^1
 ;;^UTILITY(U,$J,358.3,9703,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9703,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,9703,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,9704,0)
 ;;=J3300^^43^554^14^^^^1
 ;;^UTILITY(U,$J,358.3,9704,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9704,1,2,0)
 ;;=2^Triescence Inj per 1mg
 ;;^UTILITY(U,$J,358.3,9704,1,3,0)
 ;;=3^J3300
 ;;^UTILITY(U,$J,358.3,9705,0)
 ;;=J3301^^43^554^7^^^^1
 ;;^UTILITY(U,$J,358.3,9705,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9705,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,9705,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,9706,0)
 ;;=J3396^^43^554^15^^^^1
 ;;^UTILITY(U,$J,358.3,9706,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9706,1,2,0)
 ;;=2^Verteporfin Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,9706,1,3,0)
 ;;=3^J3396
 ;;^UTILITY(U,$J,358.3,9707,0)
 ;;=J9035^^43^554^3^^^^1
 ;;^UTILITY(U,$J,358.3,9707,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9707,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,9707,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,9708,0)
 ;;=J0178^^43^554^1^^^^1
 ;;^UTILITY(U,$J,358.3,9708,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9708,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,9708,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,9709,0)
 ;;=67028^^43^555^1^^^^1
 ;;^UTILITY(U,$J,358.3,9709,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9709,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,9709,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,9710,0)
 ;;=J9035^^43^555^3^^^^1
 ;;^UTILITY(U,$J,358.3,9710,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9710,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,9710,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,9711,0)
 ;;=J2778^^43^555^5^^^^1
 ;;
 ;;$END ROU IBDEI0KH
